Biomarin Pharmaceutical Inc (BMRN)
NASDAQ · Healthcare · Biotechnology
Biomarin Pharmaceutical Inc is a Healthcare company with a market capitalization of $12.29B and a trailing P/E ratio of 171.6.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 4, 2026 | $0.76 | $0.91 | -16.5% |
| Q4 2025 | February 23, 2026 | $0.46 | $0.81 | -43.5% |
| Q3 2025 | October 27, 2025 | $0.12 | $0.34 | -64.7% |
| Q2 2025 | August 4, 2025 | $1.44 | $1.03 | +39.8% |
| Q1 2025 | May 1, 2025 | $1.13 | $0.95 | +18.9% |
| Q4 2024 | February 19, 2025 | $0.92 | $0.74 | +24.6% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 14,315,984 | 7.24% | 10.2 | +2.9% |
| June 30, 2026 | 13,908,847 | 7.04% | 6.0 | +11.1% |
| June 15, 2026 | 12,516,448 | 6.33% | 6.1 | +7.8% |
| May 29, 2026 | 11,605,279 | 5.87% | 4.0 | +2.2% |
| May 15, 2026 | 11,359,229 | 5.75% | 5.4 | +5.3% |
| April 30, 2026 | 10,792,859 | 5.47% | 7.3 | +6.3% |
| April 15, 2026 | 10,151,216 | 5.14% | 6.4 | +14.9% |
| March 31, 2026 | 8,832,493 | 4.47% | 4.2 | +3.9% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Biomarin Pharmaceutical Inc's market cap?
As of August 13, 2026, Biomarin Pharmaceutical Inc (BMRN) has a market capitalization of $12.29B.
What is Biomarin Pharmaceutical Inc's P/E ratio?
Biomarin Pharmaceutical Inc trades at a trailing price-to-earnings (P/E) ratio of 171.6. Its forward P/E is 12.8.
Does Biomarin Pharmaceutical Inc pay a dividend?
Biomarin Pharmaceutical Inc does not currently pay a dividend.
What sector is BMRN in?
Biomarin Pharmaceutical Inc is in the Healthcare sector, specifically the Biotechnology industry.
What is Biomarin Pharmaceutical Inc's short interest?
As of the July 15, 2026 FINRA settlement, 14,315,984 BMRN shares were sold short, or 7.24% of shares outstanding. Days to cover: 10.2. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Biomarin Pharmaceutical Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Biomarin Pharmaceutical Inc reported revenue of $3.22B and net income of $348.90M.
Ask your own questions about BMRN
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.